ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022
Fair Allocation of Scarce Therapies for Coronavirus Disease 2019 (COVID-19).
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Causal Inference in Health Disparities Research.Annual review of public health · 2026Review
- A Machine Learning Method for Allocating Scarce COVID-19 Monoclonal Antibodies.JAMA health forum · 2024Article
- Benefits of near-universal vaccination and treatment access to manage COVID-19 burden in the United States.medRxiv : the preprint server for health sciences · 2023Article
- Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trial.BMJ medicine · 2023Article
- Sociodemographic Comparison of Children With High-risk Medical Conditions Referred vs Identified Through Screening Plus Outreach for COVID-19 Therapeutics.JAMA network open · 2022Article
- A Calculator for COVID-19 Severity Prediction Based on Patient Risk Factors and Number of Vaccines Received.Microorganisms · 2022Article
- Current status of antimicrobial prophylaxis during extracorporeal membrane oxygenation in Japan: a national survey.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2022Article
- Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic.Environmental research · 2022Review
- Assessment of geographic access to monoclonal antibodies in the United States.Journal of travel medicine · 2022Article
- COVID-19 vaccine: what are we doing and what should we do?The Lancet. Infectious diseases · 2022Article
- Predicting COVID-19 severity using major risk factors and received vaccines.medRxiv : the preprint server for health sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The US Food and Drug Administration (FDA) has issued emergency use authorizations (EUAs) for monoclonal antibodies (mAbs) for nonhospitalized patients with mild or moderate coronavirus disease 2019 (COVID-19) disease and for individuals exposed to COVID-19 as postexposure prophylaxis. EUAs for oral antiviral drugs have also been issued. Due to increased demand because of the Delta variant, the federal government resumed control over the supply and asked states to ration doses. As future variants (eg, the Omicron variant) emerge, further rationing may be required. We identify relevant ethical principles (ie, benefiting people and preventing harm, equal concern, and mitigating health inequities) and priority groups for access to therapies based on an integrated approach to population health and medical factors (eg, urgently scarce healthcare workers, persons in disadvantaged communities hard hit by COVID-19). Using priority categories to allocate scarce therapies effectively operationalizes important ethical values. This strategy is preferable to the current approach of categorical exclusion or inclusion rules based on vaccination, immunocompromise status, or older age, or the ad hoc consideration of clinical risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.